NCT07486713 2026-03-20Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRigel PharmaceuticalsPhase 4 Recruiting16 enrolled
NCT06161974 2025-02-21Study of Olutasidenib and Temozolomide in HGGRigel PharmaceuticalsPhase 2 Recruiting60 enrolled